JPMorgan analyst Anupam Rama lowered the firm’s price target on Amicus to $19 from $21 and keeps an Overweight rating on the shares. The analyst does not believe the shares currently reflect the near- or long-term potential of Pombiliti plus Opfolda. Launch progress with the product has the potential to grind Amicus shares to the mid- to high-teens levels, the analyst tells investors in a research note. The firm senses there are concerns on the Street regarding Pombiliti plus Opfolda meeting 2024 Street estimates, but it believes full-year sales estimates are getting into the range as “very much achievable.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on FOLD:
- Amicus Therapeutics to Present at Upcoming Investor Conferences in March 2024
- Amicus Therapeutics Announces Full-Year 2023 Financial Results and Corporate Updates
- Amicus reports Q4 EPS 1c, consensus (6c)
- FOLD Upcoming Earnings Report: What to Expect?
- Amicus Therapeutics to Announce Full Year 2023 Financial Results on February 28, 2024